Official Title Improving Physical Ability and Cellular Senescence Elimination in HIV (IPACE-HIV)

Purpose

The purpose of this study is to evaluate the safety and tolerability of dasatinib and quercetin (D+Q) and efficacy of this regimen in improving physical function outcomes in people with HIV (PWH) who are frail or prefrail.

Could this study be right for you?

• People living with HIV ≥50 years diagnosed with HIV 10 or more years ago
• Currently on combination antiretroviral therapy
• Currently virologically suppressed
• Must meet FFP criteria & have 4-meter gait speed in the range of .5-1.2 m/sec

Age Range

50 years and up

Official Title AMC-111 Impact of Behavior Modification Interventions and Lung Cancer Screening on Smoking Cessation in People Living With HIV: A Feasibility Study

Purpose

This clinical trial evaluates the usefulness of using a smartphone-based HIV-specific smoking cessation intervention at the time of lung cancer screening in helping people living with HIV quit smoking. Positively Smoke Free - Mobile may help patients with HIV quit smoking.

 

In this study, you will have lung cancer screening performed via a CT scan. You will also be enrolled into a self-guided smartphone-based HIV-specific smoking cessation intervention called “Positively Smoke Free - Mobile” lasting 42 days. After starting the intervention, you will be evaluated at 3, 6, and 12 months. 

Could this study be right for you?

Must have at least a 20 pack-year history of smoking (a way to measure how much a person has smoked over time, 1 pack-year is a pack per day for a year or 2 packs of cigarettes for half a year, etc.)

Must have not had a CT scan in the past 12 months

HIV positive, and must be receiving antiretroviral therapy and have a CD4 count of at least 200cells/uL within 6 months of enrolling in the study

Able to understand and provide informed consent

Possess a smart phone that can browse the web

Not receiving any other smoking cessation interventions currently or within the prior 30 days

Female volunteers cannot be pregnant, lactating, or breast-feeding

Age Range

45 - 80 years

Official Title Decay of HIV-1 Reservoirs in Participants on Long-Term Antiretroviral Therapy: The ACTG HIV Reservoirs Cohort (AHRC) Study

Purpose

The purpose of this study is to examine longitudinal changes in HIV-1 reservoirs among participants with HIV-1 who are either currently receiving antiretroviral therapy (ART) or who received ART previously. Participants will undergo blood and hair sample collections for immunologic, virologic, and pharmacologic evaluations to study HIV-1 reservoirs in the body.

Could this study be right for you?

This study is currently only enrolling in Group 6 which includes participants who acquired HIV while taking long-acting cabotegravir (CAB).

Age Range

18 years and up

Official Title A Double-Blind, Randomized, Placebo-Controlled Clinical Trial of Combination HIV-Specific Broadly Neutralizing Monoclonal Antibodies Combined with ART Initiation during Acute HIV Infection to Induce HIV Remission

Purpose

The purpose of this study is to evaluate the safety and efficacy of combination bNAbs in addition to ART initiated during acute HIV infection and to evaluate the impact on HIV viral reservoirs.

Could this study be right for you?

• Newly diagnosed HIV+ individuals who have not yet started antiretroviral therapy (ART)
• Willingness to start ART at enrollment
• Ability and willingness to participate in scheduled study visits and analytic treatment interruption (ATI)
• Weight <115kg

Age Range

18 - 70 years

Official Title An Open-Label, Randomized Controlled Trial of Pramipexole versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD with Mild Neurocognitive Disorder (MND) in Persons Living with HIV

Purpose

This study will evaluate the safety & efficacy of pramipexole vs. escitalopram for treatment of major depressive disorder (MDD) and comorbid MDD/mild neurocognitive disorder (MND) in people living with HIV.

Could this study be right for you?

• People living with HIV ages 18-70
• Diagnosis of MDD alone or with comorbid MDD/MND
• On ART for at least 3 months with HIV RNA <200 copies within 90 days

Age Range

18 - 70 years

Official Title A Phase I/IIa Randomized, Placebo-Controlled Trial of Conserved-Mosaic T-cell Vaccine in a Regimen with Vesatolimod and Broadly Neutralizing Antibodies in Adults Initiated on Suppressive Antiretroviral Therapy during Acute HIV-1

Purpose

This study will evaluate the safety and efficacy of these treatments in individuals with HIV-1 who started suppressive antiretroviral therapy (ART) during acute HIV-1 infection. The study consists of four steps including an analytical treatment interruption (ATI).

Could this study be right for you?

• Individuals with HIV who started treatment during acute HIV infection
• No known ART interruption >14 consecutive days since ART initiation
• Willingness to participate in analytic treatment interruption
• CD4 count ≥500 within 60 days to study entry
• HIV RNA <50 since initial viral suppression on ART and for at least 1 year prior to study entry

Age Range

18 years and up

Official Title Short-term and long-term impact of COVID-19 on multiple sensory systems

Purpose

The purpose of this study is to assess the short-term and long-term impact of COVID-19 on multiple sensory systems, including smell, taste, hearing, and balance.

The study requires about 2.5 hours of your time for your first visit, during which you may undergo smell, taste, hearing, motion, and balance tests. You may be require to participate several follow-up visits, each last 1.5 hours, if you continue to experience symptoms.

 

Could this study be right for you?

• Adults diagnosed with COVID 19 within the past 1-8 weeks
• Adults with previous COVID-19 diagnosis and has persistent (>90 days) complaints of sensory dysfunctions (smell, taste, chemesthesis, hearing, balance, dizziness)
• Adult with a recent (<8 weeks) upper respiratory infection (cold, flu, etc.)
• Adult with a previous upper respiratory infection (cold, flu, etc.) and has complaints of sensory dysfunctions (smell, taste, hearing, balance, dizziness)

Age Range

18 - 99 years

Official Title Safety, Tolerability, and Outcomes of Velpatasvir/SofosbuviR in Treatment of Chronic Hepatitis C Virus during Pregnancy (STORC), pregnant woman

Purpose

This study involves evaluating a medication for hepatitis C in pregnant women. 

If you are a pregnant woman with chronic hepatitis C and you join the study, you are consenting to enroll yourself and your baby after he/she is born.

Maternal participants will have 7 visits over approximately 7 months. Infant participants have four visits over approximately the first year of life.

Could this study be right for you?

(This is not a complete list)  

• Must be 18 - 45 years of age
• Chronic HCV infection of at least 6 months
• Singleton pregnancy at 20 + 0 to 30 + 0 weeks’ gestation
• Documented negative Hepatitis B testing for current infection (negative HBsAg test) prior to enrollment
• If living with HIV, must be on antiretroviral therapy

Exclusion Criteria (not a complete list)

• Plans to relocate away from the study site area in the next 16 months and unable/unwilling to return for study visits
• History of cirrhosis
• Known fetal chromosomal abnormality prior to enrollment

Age Range

18 - 45

Official Title Hepatitis C Virus Immunity in Women and Children

Purpose

This is a study to find out how pregnancy affects a mother’s immune system. (The “immune system” is the part of the body that fights germs.) This study is also to find out why some babies who are exposed to infections during pregnancy get infected and others do not.

To do this project we need to study some women and babies who are infected with the hepatitis C virus and others who are not. This will allow us to compare their immune systems.

Could this study be right for you?

You may be eligible to participate if you are:

PREGNANCY COHORT eligibility criteria:

1. Pregnant (enrollment preferably during 1st or 2nd trimester, but may occur as late as the delivery hospitalization)
2. HCV-RNA positive (#150) or HCV-RNA negative (#50)
3. Willing and able to attend all study visits

Exclusion criteria for mothers:

1. Inability to provide informed consent
2. Incarceration

Inclusion criteria for infants:

1. Child born to study mother

Exclusion criteria for infants:

1. In custody of county children’s services (Enrolled infants who are temporarily in custody of children’s services will not have further study blood draws, but lab results from blood tests ordered by their pediatrician may be followed to monitor the outcome of their HCV exposure. Infants who are later placed back in the custody of their mother or relative may be re-enrolled.)

NON-PREGNANCY COHORT eligibility criteria:

1. Willing and able to attend all study visits

Exclusion criteria:

1. Currently pregnant
2. Inability to provide informed consent
3. Incarceration

Official Title Randomized Proof-of-Concept Trial to Evaluate the Safety and Explore the Effectiveness of a Plant Polyphenol for COVID-19

Purpose

The purpose of this trial is to determine whether a commercially available dietary supplement may decrease the severity of patients with early COVID-19

Could this study be right for you?

Inclusion Criteria:

• Outpatients who test positive for infection with SARS-CoV-2
• Age 45 years and older
• Experiencing COVID 19 symptoms for 7 days or less, OR 72 hours of new respiratory symptoms
• Patient must have access to the internet or a smartphone to complete surveys
• English-speaking patients

Age Range

45 and up